|
Trichostatin A
|
Inhibits class I and II HDAC enzymes
|
Clinical trial-completed (NCT03838926)/Relapsed or Refractory Hematologic Malignancies
|
|
Valproic acid/VPA
|
Inhibits class I and class IIa HDACs
|
Clinical trial-completed (NCT01233609)/ Retinitis Pigmentosa
|
|
Sodium butyrate/NaB
|
Inhibits class I and class IIa HDACs
|
Clinical trial-completed NCT00800930/ Shigellosis
|
|
Suberoylanilide hydroxamic acid/SAHA/Vorinostat
|
Inhibits class I and II HDACs
|
Clinical trial-completed (NCT00106626)/ Advanced Cancer
|
|
3-Deazaneplanocin-A /DZNep
|
Inhibits EZH2 methyltransferase
|
–
|
|
Methylthioadenosine/MTA
|
Inhibits H3K4 methylase
|
Clinical trial-completed (NCT03083015)/ Necrotic Pulp
|
|
Morpholino
|
Inhibits histone acetyltransferase 7/KAT7
|
Clinical trial-completed (NCT03375255)/ Muscular Dystrophy, Duchenne
|
|
Resveratrol/RV
|
Activates sirtuin1/Sirt1
|
Clinical trial-completed (NCT01010009)/ Cognitive and Cerebral Blood Flow Effects of Resveratrol
|
|
Panobinostat/LBH589
|
Inhibits ClssI, II, and IV HDACs
|
Clinical trial-completed (NCT00840346)/ Acute Myeloblastic Leukaemia
|
|
Entinostat/SNDX-275/MS 27–275
|
Inhibits HDAC1/3
|
Clinical trial- completed (NCT02897778)/Cardiac Safety Study With Advanced Solid Tumors
|
|
Mocetinostat
|
Inhibits HDAC1 and HDAC2
|
Clinical trial-completed (NCT02303262)/ Metastatic Leiomyosarcoma
|
|
Lithium
|
Inhibits GSK3b
|
Clinical trial-completed (NCT01259388)/ Progressive Multiple Sclerosis
|
|
5-Aza-2′-deoxycytidine (5-dAzaC)
|
Inhibits DNMT
|
Clinical trial-completed (NCT00744757)/ Myelodysplastic Syndrome
|
|
GSK2879552
|
Inhibits LSD1
|
Terminated clinical trials Relapsed/Refractory Small Cell Lung Carcinoma
|
|
Tazemetostat
|
Inhibits EZH2 (PRC2 subunit)
|
Clinical trial-completed (NCT02860286)/ Relapsed or Refractory Malignant Mesothelioma
|
